Broad-Spectrum Inhibition of HIV-1 by a Monoclonal Antibody Directed against a gp120-Induced Epitope of CD4
暂无分享,去创建一个
L. Lopalco | R. Longhi | S. Canevari | S. Burastero | G. Scarlatti | P. Lusso | M. Figini | F. Sironi | B. Frigerio | D. Breda
[1] C. Fichtenbaum,et al. Phase 2a Study of the CCR5 Monoclonal Antibody PRO 140 Administered Intravenously to HIV-Infected Adults , 2010, Antimicrobial Agents and Chemotherapy.
[2] D. Ho,et al. Epitope Mapping of Ibalizumab, a Humanized Anti-CD4 Monoclonal Antibody with Anti-HIV-1 Activity in Infected Patients , 2010, Journal of Virology.
[3] L. Lopalco,et al. Protective versus pathogenic anti-CD4 immunity: insights from the study of natural resistance to HIV infection , 2009, Journal of Translational Medicine.
[4] Pham Phung,et al. Broad and Potent Neutralizing Antibodies from an African Donor Reveal a New HIV-1 Vaccine Target , 2009, Science.
[5] Clare E. Thomas. Roadblocks in HIV research: five questions , 2009, Nature Medicine.
[6] D. Kuritzkes,et al. Safety, Pharmacokinetics, and Antiretroviral Activity of Multiple Doses of Ibalizumab (formerly TNX-355), an Anti-CD4 Monoclonal Antibody, in Human Immunodeficiency Virus Type 1-Infected Adults , 2008, Antimicrobial Agents and Chemotherapy.
[7] J. Sodroski,et al. The challenges of eliciting neutralizing antibodies to HIV-1 and to influenza virus , 2008, Nature Reviews Microbiology.
[8] R. Gallo,et al. Antibodies to CD4-induced sites in HIV gp120 correlate with the control of SHIV challenge in macaques vaccinated with subunit immunogens , 2007, Proceedings of the National Academy of Sciences.
[9] P. Lusso,et al. HIV and the chemokine system: 10 years later , 2006, The EMBO journal.
[10] P. Earl,et al. Cryptic Nature of a Conserved, CD4-Inducible V3 Loop Neutralization Epitope in the Native Envelope Glycoprotein Oligomer of CCR5-Restricted, but Not CXCR4-Using, Primary Human Immunodeficiency Virus Type 1 Strains , 2005, Journal of Virology.
[11] L. Lopalco,et al. Predictive value of anti-cell and anti-human immunodeficiency virus (HIV) humoral responses in HIV-1-exposed seronegative cohorts of European and Asian origin. , 2005, The Journal of general virology.
[12] Marie-Paule Lefranc,et al. IMGT/V-QUEST, an integrated software program for immunoglobulin and T cell receptor VJ and VDJrearrangement analysis , 2004, Nucleic Acids Res..
[13] C. Broder,et al. Purified complexes of HIV-1 envelope glycoproteins with CD4 and CCR5(CXCR4): production, characterization and immunogenicity. , 2003, Vaccine.
[14] J. Gershoni,et al. Characterization of new monoclonal antibodies that discriminate between soluble and membrane CD4 and compete with human anti-CD4 autoimmune sera. , 2003, Molecular immunology.
[15] Peter D. Kwong,et al. HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites , 2002, Nature.
[16] A. Rascu,et al. Repeat-cycle study of high-dose intravenous 4162W94 anti-CD4 humanized monoclonal antibody in rheumatoid arthritis. A randomized placebo-controlled trial. , 2002, Rheumatology.
[17] C. Broder,et al. UvA-DARE ( Digital Academic Repository ) Neutralizing antibodies to the HIV-1 envelope glycoproteins , 2009 .
[18] Patrick M Liu,et al. Development of anti-CD4 MAb hu5A8 for treatment of HIV-1 infection: preclinical assessment in non-human primates. , 2002, Toxicology.
[19] M. Reitz,et al. Expression and Characterization of a Single-Chain Polypeptide Analogue of the Human Immunodeficiency Virus Type 1 gp120-CD4 Receptor Complex , 2000, Journal of Virology.
[20] K. Salzwedel,et al. Sequential CD4-Coreceptor Interactions in Human Immunodeficiency Virus Type 1 Env Function: Soluble CD4 Activates Env for Coreceptor-Dependent Fusion and Reveals Blocking Activities of Antibodies against Cryptic Conserved Epitopes on gp120 , 2000, Journal of Virology.
[21] R. Sékaly,et al. Binding of soluble recombinant HIV envelope glycoprotein, rgp120, induces conformational changes in the cellular membrane-anchored CD4 molecule. , 1999, Biochemical and biophysical research communications.
[22] J C Gluckman,et al. Rational engineering of a miniprotein that reproduces the core of the CD4 site interacting with HIV-1 envelope glycoprotein. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[23] J. Sodroski,et al. The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens. , 1998, Science.
[24] S. Canevari,et al. Panning phage antibody libraries on cells: isolation of human Fab fragments against ovarian carcinoma using guided selection. , 1998, Cancer research.
[25] E. Fenyö,et al. In vivo evolution of HIV-1 co-receptor usage and sensitivity to chemokine-mediated suppression , 1997, Nature Medicine.
[26] Joseph Sodroski,et al. CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5 , 1996, Nature.
[27] C. Broder,et al. CC CKR5: A RANTES, MIP-1α, MIP-1ॆ Receptor as a Fusion Cofactor for Macrophage-Tropic HIV-1 , 1996, Science.
[28] Paul E. Kennedy,et al. HIV-1 Entry Cofactor: Functional cDNA Cloning of a Seven-Transmembrane, G Protein-Coupled Receptor , 1996, Science.
[29] L. Lopalco,et al. Autoantibodies to CD4 in HIV type 1-exposed seronegative individuals. , 1996, AIDS research and human retroviruses.
[30] A. Trkola,et al. Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1 , 1996, Journal of virology.
[31] A. Trkola,et al. Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG , 1995, Journal of virology.
[32] C. Broder,et al. Fusogenic selectivity of the envelope glycoprotein is a major determinant of human immunodeficiency virus type 1 tropism for CD4+ T-cell lines vs. primary macrophages. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[33] S. Valitutti,et al. Distinct signaling properties identify functionally different CD4 epitopes , 1995, European journal of immunology.
[34] M. Reitz,et al. Growth of macrophage-tropic and primary human immunodeficiency virus type 1 (HIV-1) isolates in a unique CD4+ T-cell clone (PM1): failure to downregulate CD4 and to interfere with cell-line-tropic HIV-1 , 1995, Journal of virology.
[35] C. Broder,et al. Fusogenic mechanisms of enveloped-virus glycoproteins analyzed by a novel recombinant vaccinia virus-based assay quantitating cell fusion-dependent reporter gene activation , 1994, Journal of virology.
[36] J. Sodroski,et al. Immunization with a soluble CD4-gp120 complex preferentially induces neutralizing anti-human immunodeficiency virus type 1 antibodies directed to conformation-dependent epitopes of gp120 , 1994, Journal of virology.
[37] J. Gershoni,et al. HIV binding to its receptor creates specific epitopes for the CD4/gp120 complex , 1993, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[38] J. Sodroski,et al. Characterization of conserved human immunodeficiency virus type 1 gp120 neutralization epitopes exposed upon gp120-CD4 binding , 1993, Journal of virology.
[39] J. J. Rosa,et al. Inhibition of HIV infection by a novel CD4 domain 2-specific monoclonal antibody. Dissecting the basis for its inhibitory effect on HIV-induced cell fusion. , 1992, Journal of immunology.
[40] B. Moss,et al. Regulated expression of foreign genes in vaccinia virus under the control of bacteriophage T7 RNA polymerase and the Escherichia coli lac repressor , 1992, Journal of virology.
[41] Thomas P. J. Garrett,et al. Atomic structure of a fragment of human CD4 containing two immunoglobulin-like domains , 1990, Nature.
[42] F. Celada,et al. Antibody raised against soluble CD4-rgp120 complex recognizes the CD4 moiety and blocks membrane fusion without inhibiting CD4-gp120 binding , 1990, The Journal of experimental medicine.
[43] M. Skinner,et al. Neutralizing antibodies to an immunodominant envelope sequence do not prevent gp120 binding to CD4 , 1988, Journal of virology.
[44] N. Miller,et al. A monoclonal antibody to glycoprotein gp85 inhibits fusion but not attachment of Epstein-Barr virus , 1988, Journal of virology.
[45] A. Fuller,et al. Specificities of monoclonal and polyclonal antibodies that inhibit adsorption of herpes simplex virus to cells and lack of inhibition by potent neutralizing antibodies , 1985, Journal of virology.
[46] R. Lane,et al. Comparison of polyethylene glycols as fusogens for producing lymphocyte-myeloma hybrids. , 1984, Journal of immunological methods.
[47] C. Davis,et al. Antibody-mediated stripping of CD4 from lymphocyte cell surface in patients with rheumatoid arthritis. , 2003, Rheumatology.
[48] J. Farber,et al. Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. , 1999, Annual review of immunology.
[49] C. Broder,et al. CC CKR5: a RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1. , 1996, Science.